Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Plain-language summary
This trial is testing Brentuximab vedotin for patients with anaplastic large cell lymphoma (ALCL) or cutaneous T-cell lymphoma (CTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Brentuximab vedotin (DRUG): Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. | Pembrolizumab (DRUG): Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
Brentuximab vedotin, Pembrolizumab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details